Peled Amnon 4

What Happened

• Amnon Peled, a director of Silexion Therapeutics Corp (SLXN), received two grants on Feb 20, 2026: 7,576 fully vested restricted share units (RSUs) that were immediately settled for ordinary shares, and a separate grant of options covering 8,904 ordinary shares. Both grants show an acquisition price of $0.00 (standard for equity awards); the RSUs were settled into shares immediately, and the options are a derivative grant.

Key Details

• Transaction date: 2026-02-20; Form 4 filed 2026-02-23 (timely filing).
• RSU grant: 7,576 ordinary shares acquired at $0.00; settled immediately into shares (footnote F1).
• Option grant: options to purchase 8,904 ordinary shares at $0.00 reported as a derivative grant (footnotes F2–F3).
• Option terms: vest in full on the one-year anniversary of grant and expire ten years after grant approval (F3).
• Board approval: both grants were approved by Silexion’s board of directors (F1, F2).
• Shares owned after transaction: not specified in the provided filing excerpt (F4 notes certain rows included for informational purposes).

Context

• These were compensation grants (awards), not open-market purchases or sales — they represent director compensation rather than a direct market bet. The RSUs were settled immediately into shares; the options are subject to a one-year cliff vesting and long (10-year) term before expiration. No cash changed hands at grant.